<rst>
<header>
	<relations>
			<rel name="purpose" type="rst"/>
			<rel name="circumstance" type="rst"/>
			<rel name="elaboration" type="rst"/>
			<rel name="cause" type="rst"/>
			<rel name="preparation" type="rst"/>
			<rel name="restatement" type="rst"/>
			<rel name="means" type="rst"/>
			<rel name="attribution" type="rst"/>
			<rel name="contrast" type="multinuc"/>
			<rel name="joint" type="multinuc"/>
			<rel name="same_unit" type="multinuc"/>
		</relations>
</header>
<body>
<segment id="1" parent="1001" relname="preparation">3. Discussion</segment>
<segment id="2" parent="1003" relname="attribution">This study showed</segment>
<segment id="3" parent="1004" relname="span">that the cotreatment of G. lucidum extracts</segment>
<segment id="4" parent="3" relname="restatement">( GLE )</segment>
<segment id="5" parent="1006" relname="span">and quercetin</segment>
<segment id="6" parent="5" relname="restatement">( QCT )</segment>
<segment id="7" parent="1005" relname="same_unit">exerted synergistic antitumor and antiviral activities against SNU719 EBVaGC cells .</segment>
<segment id="8" parent="1007" relname="joint">Low concentrations of the cotreatment resulted in both the synergistic activation of cytotoxicity in SNU719 cells and the suppression of tumor development in MKN1-EBV xenograft mice .</segment>
<segment id="9" parent="1009" relname="preparation">The addition of a low concentration GLE to QCT reinforced QCT-mediated cytotoxicity and QCT-mediated apoptosis in SNU719 cells .</segment>
<segment id="10" parent="1010" relname="joint">Furthermore , the addition also activated the EBV lytic gene promoter</segment>
<segment id="11" parent="1010" relname="joint">and upregulated EBV genes .</segment>
<segment id="12" parent="1013" relname="span">Interestingly , ganoderic acid A</segment>
<segment id="13" parent="12" relname="elaboration">( GAA ) , an effective molecule of GLE</segment>
<segment id="14" parent="1012" relname="same_unit">also showed similar bioactive features with QCT like GLE .</segment>
<segment id="15" parent="1015" relname="span">The low concentrations of the GAA and QCT cotreatment reinforced QCT-mediated cytotoxicity and QCT-mediated apoptosis in SNU719 cells .</segment>
<segment id="16" parent="1016" relname="span">Furthermore , the cotreatment activated the EBV lytic gene promoter</segment>
<segment id="17" parent="16" relname="elaboration">and upregulated EBV genes , like GLE .</segment>
<segment id="18" parent="1018" relname="span">QCT has been shown to exhibit potential anticancer properties</segment>
<segment id="19" parent="18" relname="elaboration">owing to its antiproliferative , growth factor suppressive and antioxidant effects .</segment>
<segment id="20" parent="1020" relname="span">In addition , QCT can induce apoptosis ,</segment>
<segment id="21" parent="1021" relname="joint">where it has been shown to reduce the growth of tumors</segment>
<segment id="22" parent="1021" relname="joint">and inhibit the spread of malignant cells .</segment>
<segment id="23" parent="1023" relname="span">Moreover , it inhibited chemical carcinogen-induced cell transformation ,</segment>
<segment id="24" parent="1024" relname="same_unit">which was evident</segment>
<segment id="25" parent="26" relname="circumstance">as cell viability decreased ,</segment>
<segment id="26" parent="1025" relname="span">ROS generation and microRNA-21 elevation occurred in cancer cells .</segment>
<segment id="27" parent="1027" relname="same_unit">Besides its antitumor effects ,</segment>
<segment id="28" parent="1027" relname="same_unit">QCT has been shown to have antiviral activity through its anti-infective and anti-replicative abilities .</segment>
<segment id="29" parent="1028" relname="joint">The replication of herpes viruses , including EBV , was found to be affected by QCT .</segment>
<segment id="30" parent="1029" relname="joint">EBVaGC exhibits mixed characteristics of both gastric carcinoma and EBV .</segment>
<segment id="31" parent="1031" relname="span">Apoptosis and EBV lytic reactivation can control the fate of EBVaGC cells ,</segment>
<segment id="32" parent="1032" relname="joint">where antitumor agents can induce apoptosis</segment>
<segment id="33" parent="1033" relname="span">and antiviral agents can stimulate EBV lytic reactivation</segment>
<segment id="34" parent="33" relname="purpose">to further aggravate cell lysis .</segment>
<segment id="35" parent="1034" relname="joint">QCT exhibits both antitumor and antiviral activities against EBVaGC .</segment>
<segment id="36" parent="1035" relname="joint">This dual function of QCT is likely to be synergistic .</segment>
<segment id="37" parent="1037" relname="span">GLE , containing polysaccharides and triterpenes , is known to suppress the proliferation and metastatic potential of breast cancer cells</segment>
<segment id="38" parent="37" relname="means">by inhibiting Akt , AP-1 and NF-κB .</segment>
<segment id="39" parent="1039" relname="joint">Moreover , GLE modulated the estrogen receptor signaling</segment>
<segment id="40" parent="1039" relname="joint">and inhibited oxidative stress-induced invasiveness of breast cancer cells .</segment>
<segment id="41" parent="1041" relname="joint">Consistent with the results of previous studies on breast cancer ,</segment>
<segment id="42" parent="43" relname="attribution">our study showed</segment>
<segment id="43" parent="1042" relname="span">that GLE enhanced both QCT-mediated apoptosis and EBV-lytic reactivation .</segment>
<segment id="44" parent="1043" relname="joint">The effects of GLE were evident at low concentrations of QCT .</segment>
<segment id="45" parent="1044" relname="joint">Furthermore , QCT also enhanced the GLE-mediated upregulation of the EBV gene expression .</segment>
<segment id="46" parent="1045" relname="joint">Similarly , the effects of QCT were evident at low concentrations of GLE .</segment>
<segment id="47" parent="1048" relname="attribution">Therefore , these results suggested</segment>
<segment id="48" parent="1048" relname="contrast">that GLE enhanced QCT-mediated apoptosis ,</segment>
<segment id="49" parent="1048" relname="contrast">whereas QCT increased GLE-mediated EBV lytic reactivation .</segment>
<segment id="50" parent="1051" relname="span">Mycotherapy has several benefits ,</segment>
<segment id="51" parent="50" relname="elaboration">where it improves the overall response rate during cancer treatment ,</segment>
<segment id="52" parent="1052" relname="span">enhances immunity</segment>
<segment id="53" parent="1053" relname="joint">owing to the stimulation of T cell proliferation</segment>
<segment id="54" parent="1053" relname="joint">and reduces some chemotherapy-associated adverse events , such as nausea and insomnia .</segment>
<segment id="55" parent="1054" relname="joint">Medicinal mushrooms have mainly been used in Asian countries for hundreds of years for the treatment of infectious diseases .</segment>
<segment id="56" parent="1055" relname="joint">More recently , they have been used for cancer treatment as adjuncts .</segment>
<segment id="57" parent="1056" relname="joint">Importantly , they have an extensive clinical history of safe use as single agents or in combination with chemotherapy .</segment>
<segment id="58" parent="1057" relname="joint">GLE has been intensively combined with mycotherapy for the treatment of broad-spectrum cancers .</segment>
<segment id="59" parent="1058" relname="joint">GLE has shown antitumor activities against breast cancer , bladder cancer , prostate cancer , colorectal cancer and others .</segment>
<segment id="60" parent="1059" relname="joint">These tumor inhibitory effects of GLE were attributed to the disruption of the proliferation and metastasis of cancer cells .</segment>
<segment id="61" parent="1061" relname="span">However , the fact</segment>
<segment id="62" parent="61" relname="elaboration">that EBV is the initiator of gastric carcinoma should be considered in the treatment of EBVaGC .</segment>
<segment id="63" parent="1063" relname="span">EBV should be eliminated</segment>
<segment id="64" parent="63" relname="purpose">to reduce the risk of EBVaGC relapse .</segment>
<segment id="65" parent="1064" relname="joint">In this study , QCT strongly induced EBV lytic reactivation .</segment>
<segment id="66" parent="1065" relname="joint">The synergistic effects of the GLE and QCT cotreatment might enhance QCT-mediated apoptosis and GLE-mediated EBV lytic reactivation .</segment>
<segment id="67" parent="1067" relname="preparation">Therefore , QCT-supplemented GLE might be used as a medicinal food with a dual function as an antitumor and antiviral agent for EBVaGC treatment .</segment>
<segment id="68" parent="1068" relname="span">To the author ’s knowledge ,</segment>
<segment id="69" parent="1069" relname="span">this is the first study</segment>
<segment id="70" parent="1071" relname="attribution">to report</segment>
<segment id="71" parent="1071" relname="span">that QCT-supplemented GLE might be effective</segment>
<segment id="72" parent="71" relname="elaboration">in treating EBVaGC .</segment>
<segment id="73" parent="1073" relname="joint">The synergistic antitumor and antiviral effects were supported by both in vivo and in vitro studies .</segment>
<segment id="74" parent="1074" relname="span">Hence , the combined use of GLE and QCT could be beneficial in cancer treatment</segment>
<segment id="75" parent="1075" relname="joint">by alleviating the toxicity of conventional chemotherapy</segment>
<segment id="76" parent="1075" relname="joint">and improving the immune function .</segment>
<segment id="77" parent="1076" relname="span">However , more studies are still needed</segment>
<segment id="78" parent="77" relname="purpose">to further elucidate the molecular mechanisms of the direct antitumor and antiviral effects of QCT-supplemented GLE .</segment>
<group id="1000" type="span" />
<group id="1001" type="span" parent="1000" relname="span"/>
<group id="1002" type="span" parent="1001" relname="span"/>
<group id="1003" type="multinuc" parent="1002" relname="span"/>
<group id="1004" type="span" parent="1003" relname="same_unit"/>
<group id="1005" type="multinuc" parent="1003" relname="same_unit"/>
<group id="1006" type="span" parent="1005" relname="same_unit"/>
<group id="1007" type="multinuc" parent="1002" relname="elaboration"/>
<group id="1008" type="span" parent="1007" relname="joint"/>
<group id="1009" type="multinuc" parent="1008" relname="span"/>
<group id="1010" type="multinuc" parent="1009" relname="joint"/>
<group id="1011" type="multinuc" parent="1009" relname="joint"/>
<group id="1012" type="multinuc" parent="1011" relname="joint"/>
<group id="1013" type="span" parent="1012" relname="same_unit"/>
<group id="1014" type="multinuc" parent="1011" relname="joint"/>
<group id="1015" type="span" parent="1014" relname="joint"/>
<group id="1016" type="span" parent="15" relname="elaboration"/>
<group id="1017" type="multinuc" parent="1014" relname="joint"/>
<group id="1018" type="span" parent="1017" relname="joint"/>
<group id="1019" type="multinuc" parent="1017" relname="joint"/>
<group id="1020" type="span" parent="1019" relname="joint"/>
<group id="1021" type="multinuc" parent="20" relname="elaboration"/>
<group id="1022" type="multinuc" parent="1019" relname="joint"/>
<group id="1023" type="span" parent="1022" relname="joint"/>
<group id="1024" type="multinuc" parent="23" relname="elaboration"/>
<group id="1025" type="span" parent="1024" relname="same_unit"/>
<group id="1026" type="multinuc" parent="1022" relname="joint"/>
<group id="1027" type="multinuc" parent="1026" relname="joint"/>
<group id="1028" type="multinuc" parent="1026" relname="joint"/>
<group id="1029" type="multinuc" parent="1028" relname="joint"/>
<group id="1030" type="multinuc" parent="1029" relname="joint"/>
<group id="1031" type="span" parent="1030" relname="joint"/>
<group id="1032" type="multinuc" parent="31" relname="elaboration"/>
<group id="1033" type="span" parent="1032" relname="joint"/>
<group id="1034" type="multinuc" parent="1030" relname="joint"/>
<group id="1035" type="multinuc" parent="1034" relname="joint"/>
<group id="1036" type="multinuc" parent="1035" relname="joint"/>
<group id="1037" type="span" parent="1036" relname="joint"/>
<group id="1038" type="multinuc" parent="1036" relname="joint"/>
<group id="1039" type="multinuc" parent="1038" relname="joint"/>
<group id="1040" type="multinuc" parent="1038" relname="joint"/>
<group id="1041" type="multinuc" parent="1040" relname="joint"/>
<group id="1042" type="span" parent="1041" relname="joint"/>
<group id="1043" type="multinuc" parent="1040" relname="joint"/>
<group id="1044" type="multinuc" parent="1043" relname="joint"/>
<group id="1045" type="multinuc" parent="1044" relname="joint"/>
<group id="1046" type="multinuc" parent="1045" relname="joint"/>
<group id="1047" type="span" parent="1046" relname="joint"/>
<group id="1048" type="multinuc" parent="1047" relname="span"/>
<group id="1049" type="multinuc" parent="1046" relname="joint"/>
<group id="1050" type="multinuc" parent="1049" relname="joint"/>
<group id="1051" type="span" parent="1050" relname="same_unit"/>
<group id="1052" type="span" parent="1050" relname="same_unit"/>
<group id="1053" type="multinuc" parent="52" relname="cause"/>
<group id="1054" type="multinuc" parent="1049" relname="joint"/>
<group id="1055" type="multinuc" parent="1054" relname="joint"/>
<group id="1056" type="multinuc" parent="1055" relname="joint"/>
<group id="1057" type="multinuc" parent="1056" relname="joint"/>
<group id="1058" type="multinuc" parent="1057" relname="joint"/>
<group id="1059" type="multinuc" parent="1058" relname="joint"/>
<group id="1060" type="span" parent="1059" relname="joint"/>
<group id="1061" type="span" parent="1062" relname="preparation"/>
<group id="1062" type="span" parent="1060" relname="span"/>
<group id="1063" type="span" parent="1064" relname="preparation"/>
<group id="1064" type="multinuc" parent="1062" relname="span"/>
<group id="1065" type="multinuc" parent="1064" relname="joint"/>
<group id="1066" type="span" parent="1065" relname="joint"/>
<group id="1067" type="multinuc" parent="1066" relname="span"/>
<group id="1068" type="span" parent="1067" relname="joint"/>
<group id="1069" type="span" parent="68" relname="elaboration"/>
<group id="1070" type="span" parent="69" relname="elaboration"/>
<group id="1071" type="span" parent="1070" relname="span"/>
<group id="1072" type="multinuc" parent="1067" relname="joint"/>
<group id="1073" type="multinuc" parent="1072" relname="joint"/>
<group id="1074" type="span" parent="1073" relname="joint"/>
<group id="1075" type="multinuc" parent="74" relname="means"/>
<group id="1076" type="span" parent="1072" relname="joint"/>
	</body>
</rst>
